Cortexyme (CRTX) to Acquire Novosteo

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/25/2026

1. DECK
2. RNG
3. WDC
4. BMY
5. BYD
6. SPOT
7. WCN
8. FIX
9. TSCO
10. BE

Go back to Cortexyme (CRTX) to Acquire Novosteo

Cortexyme Announces Agreement to Acquire Novosteo

May 10, 2022 8:00 AM EDT

Expanding pipeline with addition of targeted therapeutics to treat rare skeletal diseases, bone cancer and injury

Strengthening leadership team with appointment of Novosteo executives Dr. Dirk Thye as CEO and Dr. Karen Smith as CMO of combined company

Planning corporate name change to Quince Therapeutics to reflect broadening of therapeutic pipeline

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Cortexyme, Inc. (Nasdaq: CRTX), a clinical-stage biopharmaceutical company dedicated to improving the lives of patients diagnosed with degenerative diseases, today... More